医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nitto: New Anti-fibrosis Drug with Molecular Targeting DDS Completed Phase-1a Dose Escalation

2014年04月23日 AM03:58
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Nitto Denko Corporation (Nitto) (TOKYO:6988) (ISIN:JP3684000007) has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof.Yoshiro Niitsu of Sapporo Medical University. In June 2013, Nitto initiated a phase-1 clinical study in the US, and it is happy to announce that dosing in healthy volunteers has been completed. Currently, Nitto is advancing the drug to phase-1/2 clinical study in patients for the assessment of safety and efficacy.

Nitto’s new anti-fibrotic therapy consists of siRNA which specifically inhibits the cause of fibrosis as well as a targeted lipid nanoparticle delivery system which can deliver the siRNA to the cells responsible for fibrosis. Therefore, the new drug has a dual targeting mechanism in both drug delivery and action. Furthermore, this anti-fibrosis therapy can be a revolutionary drug which leads complete resolution of liver fibrosis and other organ fibrosis, which is not available so far. Nitto also obtained relevant granted intellectual properties of therapeutic modality in Japan, US, Europe, China, Canada, Australia and Korea, as well as drug formulations including siRNA and DDS.

Nitto is also pursuing research activities in tissue regeneration mechanisms related to our therapeutic modality, in addition to new oncology programs which were derived from fibrosis drug development. Those research activities are carried out with collaborations and supports from Sapporo Medical University and Hokkaido University and others.

Nitto plans to initiate phase-1/2 clinical study in US this year in order to assess safety and efficacy in patients, and expects to collaborate with pharmaceutical company from late phase-2 stage toward approval from the agency in 2018 or after. Nitto continues to put all efforts to deliver new drugs for fibrosis and other intractable diseases to patients in need.

* Molecular Targeting DDS: A Drug Delivery System which targets to specific molecule, which enables to deliver desired amount of drug to only preferable site(s) to be delivered.
* Phase-1 clinical study: Assessment of drug safety in human
* Phase-2 clinical study: Assessment of drug efficacy in human

Nitto produces various products across a broad range of industries through a combination of technologies based on polymer synthesis, such as industrial tapes and electronics-related materials (e.g. optical films for LCDs.) In the medical field, Nitto has also been developing businesses related to transdermal drug delivery patches and nucleic acid synthesis. Nitto will capitalize on its experience in these areas to develop therapeutic agents in the future. Nitto will continue to create new value and businesses in the “Green (environmental), Clean (new energy) and Fine (life sciences)” business domains.

CONTACT

Nitto Denko Corporation
Kazuhito Kouno, +81-6-7632-2111
Brand
Strategy Dept., Corporate Strategy Management Div.
communication_group@nitto.co.jp
FAX:
+81-6-7632-2568

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆